JOSÉ TOMÁS
RAMOS AMADOR
Catedrático de universidad
French Institute of Health and Medical Research
París, FranciaPublicaciones en colaboración con investigadores/as de French Institute of Health and Medical Research (14)
2023
-
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
eClinicalMedicine, Vol. 60
-
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 <FOR VERIFICATION>years and older: a PK substudy of the SMILE trial
Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 4, pp. 1041-1049
2018
2016
-
A case of IL-7R deficiency caused by a novel synonymous mutation and implications for mutation screening in SCID diagnosis
Frontiers in Immunology, Vol. 7, Núm. OCT
-
Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption
AIDS, Vol. 30, Núm. 7, pp. 1075-1081
-
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project
BMC Infectious Diseases, Vol. 16, Núm. 1
2013
-
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children
AIDS and Behavior, Vol. 17, Núm. 1, pp. 193-202
-
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
PLoS Medicine, Vol. 10, Núm. 9
-
The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era
Clinical Infectious Diseases, Vol. 57, Núm. 7, pp. 1038-1047
2012
-
Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: Application of individualized therapy in HIV-infected infants and toddlers
British Journal of Clinical Pharmacology, Vol. 73, Núm. 4, pp. 641-650
-
Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation
Clinical Infectious Diseases, Vol. 54, Núm. 6, pp. 878-881
2011
-
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial
The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283
2009
-
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants
AIDS, Vol. 23, Núm. 5, pp. 597-604
2008
-
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
Clinical Infectious Diseases, Vol. 46, Núm. 10, pp. 1601-1608